VIP: Research & Studies

Research Overview#

Vasoactive Intestinal Peptide has been the subject of extensive research since its discovery in 1970, with over five decades of published literature spanning basic neuroscience, immunology, cardiovascular physiology, gastroenterology, and oncology. Despite this breadth of preclinical evidence, the clinical translation of VIP into approved therapeutics has been unsuccessful to date. The overall evidence level for VIP's therapeutic applications is assessed as low, reflecting the preponderance of preclinical data, the small size and methodological limitations of human studies, and the failure of the most advanced clinical trials to meet their primary endpoints.

The disconnect between robust preclinical efficacy and disappointing clinical results is largely attributable to VIP's pharmacokinetic limitations, particularly its 1-2 minute intravenous half-life and the resulting difficulty in achieving and maintaining therapeutic concentrations at target tissues. The broad tissue distribution of VPAC receptors and the resulting dose-limiting systemic vasodilation further complicate the therapeutic window.

Pulmonary Arterial Hypertension Research#

Initial Open-Label Study (Petkov et al., 2003)#

The most influential early clinical data for VIP came from an open-label study conducted by Petkov and colleagues at the University of Vienna. This study enrolled 20 patients with idiopathic pulmonary arterial hypertension who received inhaled VIP at doses of 100-200 micrograms daily for three months. The rationale was based on the observation that patients with idiopathic PAH exhibited reduced VIP expression in lung tissue and lower serum VIP levels compared to healthy controls.

The study reported significant improvements across multiple endpoints. Mean pulmonary arterial pressure decreased by approximately 13 mmHg, representing a clinically meaningful hemodynamic change. Pulmonary vascular resistance decreased in parallel, while cardiac output improved. Functionally, patients demonstrated increased 6-minute walk distance, a standard endpoint in PAH trials. Echocardiographic assessment showed improvements in right ventricular function.

These results generated considerable interest in VIP as a potential PAH therapy. However, the study's open-label design, small sample size, and lack of a placebo control group limited the strength of evidence. The placebo effect in PAH trials is well-documented, and subjective endpoints such as exercise tolerance are particularly susceptible to placebo responses.

Controlled Trial Failure#

A subsequent randomized, double-blind, placebo-controlled Phase 2 trial of inhaled aviptadil in PAH was conducted to confirm the open-label findings. This trial failed to demonstrate statistically significant improvements in the primary hemodynamic endpoints. The discrepancy between the open-label and controlled trial results may be attributed to several factors, including the placebo effect in the uncontrolled study, differences in nebulizer device and drug delivery efficiency between the two trials, the inherent difficulty in achieving sufficient pulmonary drug deposition with a rapidly degradable peptide, and the possibility that the original findings represented a type I error in a small sample.

This failure marked a significant setback for VIP's clinical development in PAH and highlighted the importance of adequate controls and sufficient statistical power in evaluating peptide-based therapies.

COVID-19 and Acute Respiratory Failure#

The ZYESAMI Trial#

The COVID-19 pandemic provided an unexpected impetus for VIP clinical research. NeuroRx Inc. sponsored a Phase 2/3 randomized, placebo-controlled trial (designated ZYESAMI) evaluating intravenous aviptadil in patients with COVID-19-associated respiratory failure requiring high-flow nasal cannula, non-invasive ventilation, or mechanical ventilation.

The scientific rationale for this trial rested on several observations. VIP is present at high concentrations in pulmonary tissue and is expressed abundantly in alveolar type II cells, the cells primarily targeted by SARS-CoV-2 infection. VIP's anti-inflammatory properties, including suppression of TNF-alpha, IL-6, and other pro-inflammatory cytokines, were theoretically relevant to the cytokine storm pathology of severe COVID-19. Additionally, VIP's capacity to protect alveolar epithelial cells from inflammatory and oxidative injury provided mechanistic plausibility for benefit in acute lung injury.

The trial enrolled patients across multiple centers and administered intravenous aviptadil using a dose-escalating infusion protocol (50-150 pmol/kg/min) over 12 hours daily for three consecutive days. The primary endpoint was survival without the need for mechanical ventilation at day 28.

Trial Results and Regulatory Outcome#

Preliminary reports from the ZYESAMI trial indicated some positive signals, including improvements in oxygenation parameters and trends toward reduced mortality in the aviptadil treatment group. However, the trial did not meet its primary endpoint of survival without mechanical ventilation at day 28 across all patient subgroups. The failure to achieve the primary endpoint meant that the totality of evidence was insufficient to support regulatory approval.

An application for Emergency Use Authorization was submitted to the FDA but was not granted. The denial reflected the lack of statistically significant efficacy on the pre-specified primary endpoint and concerns about the quality and consistency of the trial data. This outcome represented another setback for VIP clinical development and underscored the challenges of translating VIP's preclinical anti-inflammatory profile into clinical benefit.

Inflammatory Bowel Disease Research#

Preclinical Evidence#

VIP has demonstrated consistent efficacy in multiple preclinical models of inflammatory bowel disease. In the trinitrobenzene sulfonic acid (TNBS)-induced colitis model, which mimics aspects of Crohn's disease pathology, systemic VIP administration reduced macroscopic and microscopic inflammation scores, decreased tissue levels of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12, IFN-gamma), and increased levels of the anti-inflammatory cytokine IL-10.

In the dextran sodium sulfate (DSS)-induced colitis model, which produces features of ulcerative colitis, VIP similarly reduced colonic inflammation, preserved epithelial barrier integrity, and promoted mucosal healing. Mechanistic studies revealed that VIP's therapeutic effects in these models were associated with induction of regulatory T cells in the colonic lamina propria, generation of tolerogenic dendritic cells, and a shift from Th1/Th17 to Th2/Treg immune polarization in the intestinal mucosa.

Translational Challenges#

Despite strong preclinical rationale, no completed clinical trials have evaluated VIP for IBD in human patients. The principal barrier remains the pharmacokinetic challenge of delivering biologically active VIP to the intestinal mucosa. Systemic administration is limited by rapid degradation and dose-limiting hypotension. Local delivery strategies, including VIP-loaded nanoparticles designed for oral or rectal administration, represent an active area of investigation. PLGA-encapsulated VIP has shown enhanced anti-inflammatory efficacy in preclinical colitis models compared to free VIP, with sustained release profiles measured in hours rather than minutes.

Neuroprotection Research#

Alzheimer Disease Models#

VIP and its analogs have demonstrated neuroprotective efficacy in several models relevant to Alzheimer disease. In cell culture models of beta-amyloid toxicity, VIP protected hippocampal and cortical neurons from amyloid-induced apoptosis. The neuroprotective mechanism involves VIP-stimulated release of activity-dependent neuroprotective protein (ADNP) from glial cells. ADNP is itself a potent neuroprotective factor, and VIP-ADNP signaling represents a glia-mediated neuroprotective pathway. An 8-amino acid fragment of ADNP, designated NAP or davunetide, was developed as an independent therapeutic candidate and underwent clinical trials for neurodegenerative conditions.

In transgenic Alzheimer mouse models, VIP administration reduced beta-amyloid plaque burden, decreased markers of neuroinflammation (activated microglia, pro-inflammatory cytokines), and improved cognitive performance in behavioral assays including the Morris water maze and novel object recognition. The lipophilic VIP analog stearyl-norleucine-VIP (SNV) showed enhanced neuroprotective efficacy compared to native VIP, attributed to improved blood-brain barrier penetration and resistance to enzymatic degradation.

Parkinson Disease Models#

In rodent models of Parkinson disease (6-hydroxydopamine and MPTP neurotoxicity models), VIP protected dopaminergic neurons in the substantia nigra from degeneration and preserved striatal dopamine levels. The neuroprotective effect was associated with reduced microglial activation and suppression of neuroinflammatory mediators in the nigrostriatal pathway. These findings suggest that VIP's anti-neuroinflammatory properties, rather than direct neuronal effects alone, contribute substantially to its neuroprotective efficacy.

Clinical Translation Limitations#

The neuroprotection research for VIP remains entirely preclinical. The blood-brain barrier presents an additional pharmacokinetic barrier for CNS-targeted VIP therapy, as native VIP has limited brain penetration following systemic administration. Intranasal delivery has been explored as a potential route to bypass the blood-brain barrier, but this approach remains in early experimental stages. Furthermore, the clinical failure of davunetide (the ADNP-derived peptide whose expression is regulated by VIP) in a Phase 2/3 trial for progressive supranuclear palsy, while not a direct test of VIP itself, cast doubt on the translational potential of this neuroprotective pathway.

Evidence Quality Assessment#

The overall evidence for VIP's therapeutic potential is classified as low based on the following considerations:

• Preclinical evidence: Extensive and consistent across multiple disease models, species, and laboratories. The mechanistic basis for VIP's vasodilatory, anti-inflammatory, immunomodulatory, and neuroprotective effects is well-characterized at the molecular level. Preclinical evidence alone would be rated moderate to high.
• Clinical evidence: Very limited. The two most advanced clinical programs (inhaled VIP for PAH and intravenous aviptadil for COVID-19) both failed to meet primary endpoints in controlled trials. No randomized controlled trial has demonstrated unambiguous therapeutic efficacy for VIP in any indication.
• Study quality: The positive clinical results that exist (open-label PAH study) lack adequate controls and statistical power. The controlled trials that were conducted produced negative or ambiguous results.
• Reproducibility: The inability to replicate the open-label PAH findings in a controlled setting raises concerns about the robustness of VIP's clinical effects.

Research Gaps#

Several critical gaps in the VIP research base remain unaddressed. No adequately powered, randomized controlled trials have demonstrated clear therapeutic efficacy for any indication. Long-term safety data for chronic VIP administration are entirely absent. Optimal delivery methods and formulations have not been established through systematic clinical evaluation. The relative contributions of VPAC1 versus VPAC2 signaling to therapeutic effects are poorly defined, limiting rational analog design. Head-to-head comparisons between native VIP and receptor-selective analogs are needed to determine whether selectivity improves the therapeutic window. The effects of chronic exogenous VIP on immune surveillance, tumor biology, and neuroendocrine homeostasis represent important unknowns that must be addressed before any long-term therapeutic application can be considered safe.

Related Reading#

• VIP overview and research guide
• VIP dosing protocols
• VIP molecular structure